Join the Colorectal Cancer group to help and get support from people like you.
Colorectal Cancer News (Page 8)
Related terms: Cancer, Anal, Cancer, Colon, Cancer, Colorectal, Cancer, Rectal, Colon Cancer, Colon Carcinoma, Colorectal Carcinoma, Rectal Cancer
At-Home Colon Cancer Test Can Save Lives
FRIDAY, July 26, 2024 – A simple home screening test for colon cancer can reduce the risk of dying from the disease by 33%, a new study shows. Results indicate that undergoing annual at-home FIT...
Better Screening Key to Closing U.S. 'Race Gap' in Colon Cancer Deaths
WEDNESDAY, July 24, 2024 – Black Americans are almost a third more likely to die from colon cancer than their white peers, and one key to closing that divide could be better cancer screening, a new...
FIT Screening Cuts Risk of Death From Colorectal Cancer
TUESDAY, July 23, 2024 – Screening with fecal immunochemical tests (FITs) lowers the risk of dying from colorectal cancer (CRC), according to a study published online July 19 in JAMA Network Open. ...
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of Krazati (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J.--(BUSINESS WIRE) June 21, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Krazati® ...
FDA Approves Fruzaqla (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
OSAKA, Japan and CAMBRIDGE, Massachusetts, November 8, 2023 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved Fruzaqla™ (fruquintinib), an oral...
FDA Approves Lonsurf (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)
Approval clinical trial showing that treatment with Lonsurf plus bevacizumab resulted in statistically significant and clinically meaningful improvements in overall survival in patients with...
Seagen Announces FDA Accelerated Approval of Tukysa (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
BOTHELL, Wash.--(BUSINESS WIRE) January 19, 2023 – Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tukysa (tucatinib)...
FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
FDA Approves Braftovi (encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
April 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for t...
FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin
Friday, June 28, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved Zirabev (bevacizumab-bvzr), a biosimilar to...
Spectrum Pharmaceuticals Receives FDA Approval of Khapzory (levoleucovorin) for Injection
HENDERSON, Nev.--(BUSINESS WIRE)--Oct. 23, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a...
Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Combination Approved for Previously Treated MSI-H/dMMR Metastatic Colorectal Cancer
PRINCETON, N.J.-- July 11, 2018 (BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for...
FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 – The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is...
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment
PRINCETON, N.J.--(BUSINESS WIRE) August 1, 2017 – Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for...